Benitec Biopharma Ltd ADR (BNTC)

2.79
+0.04(+1.45%)
Pre Market
2.91
+0.12(+4.30%)
- Real-time Data
  • Volume:
    199,412
  • Bid/Ask
    2.57/2.91
  • Day's Range
    2.74 - 2.93

BNTC Overview

Prev. Close
2.79
Day's Range
2.74 - 2.93
Revenue
180K
Open
2.88
52 wk Range
2.3 - 17.39
EPS
0
Volume
199,412
Market Cap
6.43M
Dividend (Yield)
N/A (N/A)
Average Volume (3m)
586,093
P/E Ratio
N/A
Beta
1.65
1-Year Change
-62.8%
Shares Outstanding
4,540,469
Next Earnings Date
02 Jun 2021
What is your sentiment on Benitec Biopharma Ltd ADR?
or
Market is currently closed. Voting is open during market hours.

Benitec Biopharma Ltd ADR News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong SellSellStrong BuyStrong SellStrong Sell
SummaryStrong SellNeutralNeutralStrong SellStrong Sell

Benitec Biopharma Ltd ADR Company Profile

Benitec Biopharma Ltd ADR Company Profile

Employees
13

Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.